"BEYOND THE PRESCRIPTION: PATIENT PREFERENCES FOR PLACEBO OR ANTIPSYCHOTIC TREATMENT"

Main Article Content

Syed Akif Uddin
Syeda Tayyaba Asif
Madiha Jamshed
Maria Khan
Madiha Khan
Humera Naz

Keywords

Placebo, Antipsychotic drugs, Mental health, Schizophrenia, Bipolar disorder, Depression.

Abstract

Objective: To assess individual needs for antipsychotic medications against placebo for problems with mental health and investigate the variables influencing these choices.


Method: Data from patients with mental health issues was gathered using an electronic cross-sectional questionnaire. Convenience and snowball sampling techniques were used to find participants using social media and online discussion boards. The requirements for inclusion included being between the ages of 18 and 65 and having a diagnosis of schizophrenia, bipolar disorder, depression, or anxiety. Serious psychological disease, cognitive deterioration, and no prior experience with antipsychotic treatment were among the exclusion criteria. Participants spent six weeks filling out the online survey.


Result: The findings demonstrated that a sizable percentage of patients (60%) would rather get placebo therapies than antipsychotic medications due to side effect concerns (55%), and that placebo is a good substitute for antipsychotic drugs (50%). Patients who favored placebo interventions were less likely to adhere to their therapy regimens and were more likely to have encountered antipsychotic medication adverse effects.


Conclusion: Upcoming studies and medical procedures will be significantly impacted by the review's conclusions. The value of shared decision-making and patient-centered care, and imply that for certain patients, placebo treatments might be a good substitute for antipsychotic drugs. The possible advantages and drawbacks of placebo therapy for mental health issues require more investigation.

Abstract 154 | pdf Downloads 39

References

1. Barlow, D. H., et al. (2018). "Evidence-based psychological treatments: An update and a way forward." The Neurotic Paradox, Vol 2: 441-472.
2. Bishop, F. L., et al. (2014). "Placebo use in the UK: a qualitative study exploring GPs’ views on placebo effects in clinical practice." Family practice 31(3): 357-363.
3. Blease, C., et al. (2016). "Are open‐label placebos ethical? Informed consent and ethical equivocations." Bioethics 30(6): 407-414.
4. Colloca, L. (2019). "The placebo effect in pain therapies." Annual review of pharmacology and toxicology 59(1): 191-211.
5. Correll, C. U., et al. (2018). "What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?" World Psychiatry 17(2): 149-160.
6. Firth, J., et al. (2019). "The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta‐review of meta‐analyses of randomized controlled trials." World Psychiatry 18(3): 308-324.
7. Healy, D. (2022). "Psychiatric Drugs Explained-E-Book: Psychiatric Drugs Explained-E-Book."
8. Mandal, P. K., et al. (2022). "Schizophrenia, bipolar and major depressive disorders: overview of clinical features, neurotransmitter alterations, pharmacological interventions, and impact of oxidative stress in the disease process." ACS Chemical Neuroscience 13(19): 2784-2802.
9. Samara, M. T., et al. (2016). "Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis." JAMA psychiatry 73(3): 199-210.
10. Siafis, S., et al. (2018). "Antipsychotic drugs: from receptor-binding profiles to metabolic side effects." Current neuropharmacology 16(8): 1210-1223.
11. Theodosis-Nobelos, P., et al. (2021). "The placebo phenomenon and the underlying mechanisms." Hormones 20(1): 61-71.
12. Velligan, D. I., et al. (2017). "Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness." Patient preference and adherence: 449-468.
13. Voineskos, A. N., et al. (2020). "Effects of antipsychotic medication on brain structure in patients with major depressive disorder and psychotic features: neuroimaging findings in the context of a randomized placebo-controlled clinical trial." JAMA psychiatry 77(7): 674-683.